<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623322</url>
  </required_header>
  <id_info>
    <org_study_id>GV29893</org_study_id>
    <secondary_id>2016-000425-40</secondary_id>
    <nct_id>NCT02623322</nct_id>
  </id_info>
  <brief_title>A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled single dose study in
      otherwise healthy adults with acute uncomplicated seasonal influenza A to assess the safety
      and tolerability, efficacy, and pharmacokinetics of MHAA4549A.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2016</start_date>
  <completion_date type="Actual">November 13, 2017</completion_date>
  <primary_completion_date type="Actual">November 13, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline to Day 100</time_frame>
    <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Hospitalization for Influenza-Related Complications</measure>
    <time_frame>Baseline to Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization for Influenza-Related Complications</measure>
    <time_frame>Baseline to Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Antibiotics for Secondary Bacterial Respiratory Infections</measure>
    <time_frame>Baseline to Day 100</time_frame>
    <description>Participants with antibiotic usage for secondary bacterial respiratory infections were identified by counting participants with AEs containing the terms, &quot;pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complications of Influenza</measure>
    <time_frame>Baseline to Day 100</time_frame>
    <description>Participants with complications of influenza were identified by counting participants with AEs containing the terms, &quot;pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Influenza A Relapse/Reinfection</measure>
    <time_frame>Baseline to Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC) of MHAA4549A</measure>
    <time_frame>Up to Day 100 (collections scheduled pre-dose [0 hours]; 60 minutes post-dose; and on Days 3, 5, 7, 30, and 100 post-dose; infusion duration = 2 hours)</time_frame>
    <description>The AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. AUC was measured in micrograms times hours per milliliter (mcg*h/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of MHAA4549A</measure>
    <time_frame>Up to Day 100 (collections scheduled pre-dose [0 hours]; 60 minutes post-dose; and on Days 3, 5, 7, 30, and 100 post-dose; infusion duration = 2 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of Symptoms of Influenza A Infection</measure>
    <time_frame>Baseline to Day 14</time_frame>
    <description>Time to alleviation of all 7 symptoms (i.e., nasal congestion, sore throat, cough, aches, fatigue, headaches, chills/sweats) was assessed using a rating scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe) for each symptom. The outcome was defined in two ways: time to a total symptom score of &lt;=1 and time to a total symptom score of &lt;=7. Resolution had to be maintained for 24 hours without use of symptom relief medications. For participants who were enrolled with mild symptoms, the symptom score had to be reduced by one point during the study duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Influenza-Related Deaths</measure>
    <time_frame>Baseline to Day 100</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Influenza A</condition>
  <arm_group>
    <arm_group_label>MHAA4549A 3600 milligrams (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single-dose MHAA4549A, 3600 mg, by intravenous (IV) administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MHAA4549A 8400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single-dose MHAA4549A, 8400 mg, by IV administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive single-dose placebo by IV administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MHAA4549A</intervention_name>
    <description>MHAA4549A will be administered as a single dose by IV administration.</description>
    <arm_group_label>MHAA4549A 3600 milligrams (mg)</arm_group_label>
    <arm_group_label>MHAA4549A 8400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as a single dose by IV administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy participants

          -  Positive test for influenza A infection

          -  No more than 72 hours elapsed between onset of influenza-like illness and start of
             study drug

          -  Presence of at least one moderate or severe constitutional symptom such as headache,
             myalgia, fever, chills, fatigue, anorexia, or nausea PLUS one moderate or severe
             respiratory symptom such as cough, sore throat, or rhinorrhea

          -  For women of childbearing potential: negative pregnancy test and agreement to use
             acceptable contraceptive methods for at least 120 days after study drug administration

          -  For men: agreement to use acceptable contraceptive methods for at least 30 days after
             study drug administration

        Exclusion Criteria:

          -  Creatinine clearance less than or equal to (&lt;/=) 80 milliliters per minute (mL/min)

          -  Any significant medical conditions or laboratory abnormalities

          -  Clinical signs and symptoms consistent with otitis, bronchitis, sinusitis, or
             pneumonia or active bacterial infection

          -  Use of antiviral therapy in the period from onset of influenza-like illness and prior
             to enrollment

          -  Pregnancy at Screening or is currently pregnant or breastfeeding

          -  Investigational therapy within 30 days or 5 half-lives prior to start of study drug,
             whichever is greater

          -  Prior anti-influenza monoclonal antibody use

          -  Receipt of a nasal influenza A vaccine within 14 days prior to Screening

          -  Positive test for influenza B or influenza A+B within 2 weeks prior to study drug

          -  History of significant tobacco use or drug/alcohol abuse

          -  Chronic use of oral or inhaled corticosteroids within 30 days prior to Screening

          -  Autoimmune disease, known immunodeficiency of any cause, or use of immunosuppressive
             medications

          -  History of any chronic respiratory condition

          -  Human immunodeficiency virus (HIV) with cluster of differentiation (CD) 4 count &lt;/=
             200 cells per milliliter (cells/mL) in the past 12 months

          -  Serious infection requiring oral or IV antibiotics within 14 days prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Alabama Research Center LLC</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <zip>35611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WCCT Global, LLC</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lalla-Reddy Medical Corporation</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe Research Centers</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrity Clinical Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Community Research Of South Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research, Inc.</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Research Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oceane7 Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Internists</name>
      <address>
        <city>Saint Cloud</city>
        <state>Florida</state>
        <zip>34769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute, Inc.</name>
      <address>
        <city>Trinity</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinical Research Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Research Network of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Lung Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acadiana Medicine Clinic</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <zip>70570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center; Anne Arundel Health System</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Grace Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical Group</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrett Clinic, P.C.</name>
      <address>
        <city>La Vista</city>
        <state>Nebraska</state>
        <zip>68128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Medical Institutes, LLC</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Medical Research LLC</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency MD</name>
      <address>
        <city>Boiling Springs</city>
        <state>South Carolina</state>
        <zip>29316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCCA Clinical Research Solutions</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions, LLC</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies</name>
      <address>
        <city>Pharr</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6J 1S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q and T Research</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>inVentiv Health Clinique</name>
      <address>
        <city>Quebec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang-si</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon-si,</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henderson Medical Centre</name>
      <address>
        <city>Auckland</city>
        <zip>0612</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RMC Medical Research Ltd</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauranga Hospital</name>
      <address>
        <city>Tauranga</city>
        <zip>3143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johese Clinical Research</name>
      <address>
        <city>Centurion</city>
        <zip>1692</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durban International Clinical Research Site</name>
      <address>
        <city>Durban</city>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vawda Z Private Practice</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Peter John Sebastian; Dr PJ Sebastian</name>
      <address>
        <city>Durban</city>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Into Research; Life Groenkloof Hospital Medical Centre</name>
      <address>
        <city>Groenkloof</city>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthwhile Clinical Trials</name>
      <address>
        <city>Johannesburg</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newtown Clinical Research</name>
      <address>
        <city>Johannesburg</city>
        <zip>2113</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinresco Centres (Pty) Ltd</name>
      <address>
        <city>Kempton Park</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peermed Clinical Trial Centre</name>
      <address>
        <city>Kempton Park</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klerksdorp /Tshepong Hospital Complex</name>
      <address>
        <city>Klerksdorp</city>
        <zip>2574</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJW Navorsing</name>
      <address>
        <city>Krugersdorp</city>
        <zip>1739</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I Engelbrecht Research</name>
      <address>
        <city>Lyttleton</city>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syzygy Clinical Research; Unit 3 to 7</name>
      <address>
        <city>Pretoria Gauteng Province</city>
        <zip>0087</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jongaie Research</name>
      <address>
        <city>Pretoria-West</city>
        <zip>0183</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queenswood CTC</name>
      <address>
        <city>Queenswood</city>
        <zip>0121</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welkom Clinical Trial Centre</name>
      <address>
        <city>Welkom</city>
        <zip>9460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa; Servicio de Oncologia</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro</name>
      <address>
        <city>Logroño</city>
        <state>LA Rioja</state>
        <zip>26006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Galdacao</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surrey Clinical Research Centre; University of Surrey</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and the London NHS Trust.</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesborough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <results_first_submitted>October 31, 2018</results_first_submitted>
  <results_first_submitted_qc>December 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02623322/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 34 investigational sites in 6 countries including the United States (15 centers), South Africa (12 centers), Canada, Spain, New Zealand (2 centers in each country), and Great Britain (1 center).</recruitment_details>
      <pre_assignment_details>Randomization was stratified by onset of influenza-like illness (≤ 36 hours and &gt; 36 hours) and a permuted block randomization method was used to obtain an approximate 1:1:1 ratio of subjects in the 3600 mg MHAA4549A, 8400 mg MHAA4549A, and placebo strata.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
        </group>
        <group group_id="P2">
          <title>MHAA4549A 3600 mg</title>
          <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
        </group>
        <group group_id="P3">
          <title>MHAA4549A 8400 mg</title>
          <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population included all participants randomized to treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
        </group>
        <group group_id="B2">
          <title>MHAA4549A 3600 mg</title>
          <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
        </group>
        <group group_id="B3">
          <title>MHAA4549A 8400 mg</title>
          <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="10.8"/>
                    <measurement group_id="B2" value="36.5" spread="12.5"/>
                    <measurement group_id="B3" value="35.0" spread="13.6"/>
                    <measurement group_id="B4" value="37.0" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Stated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.</description>
        <time_frame>Baseline to Day 100</time_frame>
        <population>The safety population included all participants randomized to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O3">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug.</description>
          <population>The safety population included all participants randomized to treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="39.0"/>
                    <measurement group_id="O3" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Hospitalization for Influenza-Related Complications</title>
        <time_frame>Baseline to Day 100</time_frame>
        <population>The intent-to-treat infected (ITTI) population included all randomized participants who had an influenza A infection confirmed by central polymerase chain reaction (PCR).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O3">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Hospitalization for Influenza-Related Complications</title>
          <population>The intent-to-treat infected (ITTI) population included all randomized participants who had an influenza A infection confirmed by central polymerase chain reaction (PCR).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization for Influenza-Related Complications</title>
        <time_frame>Baseline to Day 100</time_frame>
        <population>The intent-to-treat infected (ITTI) population included all randomized participants who had an influenza A infection confirmed by central polymerase chain reaction (PCR).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O3">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization for Influenza-Related Complications</title>
          <population>The intent-to-treat infected (ITTI) population included all randomized participants who had an influenza A infection confirmed by central polymerase chain reaction (PCR).</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Antibiotics for Secondary Bacterial Respiratory Infections</title>
        <description>Participants with antibiotic usage for secondary bacterial respiratory infections were identified by counting participants with AEs containing the terms, &quot;pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory.&quot;</description>
        <time_frame>Baseline to Day 100</time_frame>
        <population>The intent-to-treat infected (ITTI) population included all randomized participants who had an influenza A infection confirmed by central PCR.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O3">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Antibiotics for Secondary Bacterial Respiratory Infections</title>
          <description>Participants with antibiotic usage for secondary bacterial respiratory infections were identified by counting participants with AEs containing the terms, &quot;pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory.&quot;</description>
          <population>The intent-to-treat infected (ITTI) population included all randomized participants who had an influenza A infection confirmed by central PCR.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.32" upper_limit="11.28"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="6.37"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3031</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in event rates (Wald)</param_type>
            <param_value>-3.03</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.25</ci_lower_limit>
            <ci_upper_limit>6.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3324</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in event rates (Wald)</param_type>
            <param_value>-3.03</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.82</ci_lower_limit>
            <ci_upper_limit>6.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complications of Influenza</title>
        <description>Participants with complications of influenza were identified by counting participants with AEs containing the terms, &quot;pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory.&quot;</description>
        <time_frame>Baseline to Day 100</time_frame>
        <population>ITTI population included all randomized participants who had an influenza A infection confirmed by central PCR.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O3">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complications of Influenza</title>
          <description>Participants with complications of influenza were identified by counting participants with AEs containing the terms, &quot;pneumonia, lung, myocarditis, ARDS (acute respiratory distress syndrome), otitis media, or respiratory.&quot;</description>
          <population>ITTI population included all randomized participants who had an influenza A infection confirmed by central PCR.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.32" upper_limit="11.28"/>
                    <measurement group_id="O2" value="0" lower_limit="0.00" upper_limit="6.37"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3031</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in event rates (Wald)</param_type>
            <param_value>-3.03</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.25</ci_lower_limit>
            <ci_upper_limit>6.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3324</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in event rates (Wald)</param_type>
            <param_value>-3.03</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.82</ci_lower_limit>
            <ci_upper_limit>6.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Influenza A Relapse/Reinfection</title>
        <time_frame>Baseline to Day 100</time_frame>
        <population>ITTI population included all randomized participants who had an influenza A infection confirmed by central PCR.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O3">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Influenza A Relapse/Reinfection</title>
          <population>ITTI population included all randomized participants who had an influenza A infection confirmed by central PCR.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve (AUC) of MHAA4549A</title>
        <description>The AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. AUC was measured in micrograms times hours per milliliter (mcg*h/mL).</description>
        <time_frame>Up to Day 100 (collections scheduled pre-dose [0 hours]; 60 minutes post-dose; and on Days 3, 5, 7, 30, and 100 post-dose; infusion duration = 2 hours)</time_frame>
        <population>Data were collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve (AUC) of MHAA4549A</title>
          <description>The AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. AUC was measured in micrograms times hours per milliliter (mcg*h/mL).</description>
          <population>Data were collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration (Cmax) of MHAA4549A</title>
        <time_frame>Up to Day 100 (collections scheduled pre-dose [0 hours]; 60 minutes post-dose; and on Days 3, 5, 7, 30, and 100 post-dose; infusion duration = 2 hours)</time_frame>
        <population>The pharmacokinetic (PK)−evaluable population included all participants who received MHA4549A.</population>
        <group_list>
          <group group_id="O1">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax) of MHAA4549A</title>
          <population>The pharmacokinetic (PK)−evaluable population included all participants who received MHA4549A.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1050" spread="299"/>
                    <measurement group_id="O2" value="2190" spread="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Alleviation of Symptoms of Influenza A Infection</title>
        <description>Time to alleviation of all 7 symptoms (i.e., nasal congestion, sore throat, cough, aches, fatigue, headaches, chills/sweats) was assessed using a rating scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe) for each symptom. The outcome was defined in two ways: time to a total symptom score of &lt;=1 and time to a total symptom score of &lt;=7. Resolution had to be maintained for 24 hours without use of symptom relief medications. For participants who were enrolled with mild symptoms, the symptom score had to be reduced by one point during the study duration.</description>
        <time_frame>Baseline to Day 14</time_frame>
        <population>ITTI population included all randomized participants who had an influenza A infection confirmed by central PCR. Data are reported for evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O3">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of Symptoms of Influenza A Infection</title>
          <description>Time to alleviation of all 7 symptoms (i.e., nasal congestion, sore throat, cough, aches, fatigue, headaches, chills/sweats) was assessed using a rating scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe) for each symptom. The outcome was defined in two ways: time to a total symptom score of &lt;=1 and time to a total symptom score of &lt;=7. Resolution had to be maintained for 24 hours without use of symptom relief medications. For participants who were enrolled with mild symptoms, the symptom score had to be reduced by one point during the study duration.</description>
          <population>ITTI population included all randomized participants who had an influenza A infection confirmed by central PCR. Data are reported for evaluable participants.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Symptom Score of &lt;=1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.30" lower_limit="108.62" upper_limit="157.15"/>
                    <measurement group_id="O2" value="153.80" lower_limit="125.52" upper_limit="175.23"/>
                    <measurement group_id="O3" value="145.82" lower_limit="132.98" upper_limit="156.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Symptom Score of &lt;=7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.50" lower_limit="27.23" upper_limit="58.65"/>
                    <measurement group_id="O2" value="74.18" lower_limit="64.32" upper_limit="87.98"/>
                    <measurement group_id="O3" value="65.59" lower_limit="44.12" upper_limit="87.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Symptom Score of &lt;=1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7858</p_value>
            <method>Wilcoxon</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Total Symptom Score of &lt;=1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5170</p_value>
            <method>Wilcoxon</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Symptom Score of &lt;=7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0312</p_value>
            <method>Wilcoxon</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Total Symptom Score of &lt;=7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2044</p_value>
            <method>Wilcoxon</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Influenza-Related Deaths</title>
        <time_frame>Baseline to Day 100</time_frame>
        <population>The safety population included all participants randomized to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
          </group>
          <group group_id="O2">
            <title>MHAA4549A 3600 mg</title>
            <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
          </group>
          <group group_id="O3">
            <title>MHAA4549A 8400 mg</title>
            <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Influenza-Related Deaths</title>
          <population>The safety population included all participants randomized to treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Day 100</time_frame>
      <desc>The safety population included all participants randomized to treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received single-dose placebo by intravenous (IV) administration.</description>
        </group>
        <group group_id="E2">
          <title>MHAA4549A 3600 mg</title>
          <description>Participants received single-dose MHAA4549A, 3600 milligrams (mg), by IV administration.</description>
        </group>
        <group group_id="E3">
          <title>MHAA4549A 8400 mg</title>
          <description>Participants received single-dose MHAA4549A, 8400 mg, by IV administration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>(+41) 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

